| __timestamp | Catalent, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 334800000 | 2917513 |
| Thursday, January 1, 2015 | 337300000 | 7878291 |
| Friday, January 1, 2016 | 358100000 | 8366794 |
| Sunday, January 1, 2017 | 402600000 | 6610381 |
| Monday, January 1, 2018 | 462600000 | 6556000 |
| Tuesday, January 1, 2019 | 512000000 | 6930000 |
| Wednesday, January 1, 2020 | 577900000 | 8758000 |
| Friday, January 1, 2021 | 687000000 | 10806000 |
| Saturday, January 1, 2022 | 844000000 | 9844000 |
| Sunday, January 1, 2023 | 831000000 | 13481000 |
| Monday, January 1, 2024 | 935000000 |
Data in motion
In the ever-evolving landscape of the pharmaceutical industry, operational efficiency is paramount. Over the past decade, Catalent, Inc. has consistently outpaced Soleno Therapeutics, Inc. in terms of Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Catalent's SG&A expenses surged by approximately 180%, reflecting its expansive growth strategy. In contrast, Soleno's expenses grew by about 360%, albeit from a much smaller base, indicating a different scale of operations.
Catalent's peak in 2024, with expenses nearing $935 million, underscores its robust market presence. Meanwhile, Soleno's expenses, peaking at $13.5 million in 2023, highlight its focused yet limited operational scope. The absence of data for Soleno in 2024 suggests a potential shift or strategic pivot. This comparative analysis offers a window into the strategic priorities and market positioning of these two distinct players.
Comparing SG&A Expenses: AbbVie Inc. vs Catalent, Inc. Trends and Insights
Zoetis Inc. vs Soleno Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Soleno Therapeutics, Inc.
Breaking Down SG&A Expenses: Genmab A/S vs Catalent, Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Walgreens Boots Alliance, Inc.
Breaking Down SG&A Expenses: Catalent, Inc. vs Veracyte, Inc.
Operational Costs Compared: SG&A Analysis of Ionis Pharmaceuticals, Inc. and Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Soleno Therapeutics, Inc.
Xenon Pharmaceuticals Inc. vs Soleno Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Soleno Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Soleno Therapeutics, Inc. vs Galapagos NV